PIQ proteomics international laboratories ltd

Very true @katy,It looks like the fast track review for Invokana...

  1. 6,434 Posts.
    lightbulb Created with Sketch. 5274
    Very true @katy,

    It looks like the fast track review for Invokana for CKD/DKD & CVD is well underway in EU:

    https://www.businesswire.com/news/home/20191009005652/en/Mundipharma-Swissmedic-reviewing-licence-extension-SGLT2-inhibitor

    I don’t know if the EMA takes around the same timeframe as FDA?, that is approximately 6 months. This licence extension application for Invokana in EU was announced by Janssen in August 2019. I can’t see that not happening with FDA approval already granted on the back of CREDENCE data.

    As we are all set with CE approval for PromarkerD in the EU, I guess potentially things could move forward there first as a CDx, however the test is already licensed & being used as a stand alone test regardless for DKD, and income trickling in already from the last quarterly (posted by @brahms & @Eqz on another thread, thanks guys).

    I can see this snowballing in the near future.

    Volumes of research coming out now on CKD/DKD & ESRD globally & how to address this problem. I think PromarkerD holds part of that key in early detection & the potential now to treat it before ESRD.

    GLTAH




 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
36.0¢
Change
-0.010(2.70%)
Mkt cap ! $58.92M
Open High Low Value Volume
37.0¢ 37.0¢ 36.0¢ $42.78K 116.3K

Buyers (Bids)

No. Vol. Price($)
1 1408 35.5¢
 

Sellers (Offers)

Price($) Vol. No.
37.0¢ 111109 2
View Market Depth
Last trade - 13.47pm 31/07/2025 (20 minute delay) ?
PIQ (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.